Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  PI3K delta/gamma inhibitor IPI-145
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-07, NCI-2014-00977, NCT02004522
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-08, NCI-2015-00134, 2013-002406-31, NCT02204982
IPI-145 with Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 14-193, NCI-2014-01565, NCT02158091
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-06, NCI-2013-02094, NCT01882803
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IPI-145-18, NCI-2015-00244, NCT02292225
Start Over